Early discovery, early diagnosis and early treatment have greatly improved the 5-year cure rate of malignant tumors, which has become a controllable “chronic disease”. Oncologists emphasize that many malignant tumors are preventable and controllable by maintaining a healthy lifestyle and diet, insisting on medical checkups, and dealing with precancerous lesions in time. Regular physical examination, checking tumor markers Tumor markers are one of the effective means to detect the presence of malignant tumors in the body. Different combinations of tumor markers suggest tumors in different parts of the body, which can be checked once a year. Of course, it doesn’t mean that a higher tumor marker means 100% malignant tumor, and further diagnosis is needed. Nowadays, people pay more attention to malignant tumors, and there are some phenomena of excessive examination and excessive panic, which are not desirable. If the tester happens to have inflammation in the body when the tumor marker is tested, the tumor marker may also be elevated. As long as it is not rapidly and persistently elevated, it is not necessarily a malignant tumor. Of course, it is prudent to have a shorter time interval for follow-up after the tumor marker is elevated. For example, normal people over 45 years old should have colonoscopy every 5 years to prevent colorectal cancer, and after the tumor marker is elevated, it can be brought forward to 1 colonoscopy in 2 years, and if you are not assured of it, you can have it once in 1 year but it is not necessary to have it checked every month at all. Malignant tumors require multidisciplinary comprehensive treatment Malignant tumors are a class of systemic diseases, and it is difficult to achieve a tumor cure by a single means of treatment. At the end of the last century, many medical scientists and famous scholars and professors put forward the principle of multidisciplinary comprehensive treatment. That is, according to the patient’s physical condition, the pathological type of tumor, the scope of invasion (stage of disease) and the development trend, the existing therapeutic means should be applied in a planned and reasonable way, with a view to increasing the cure rate of the tumor, prolonging the survival period and improving the patient’s quality of life. Multidisciplinary comprehensive treatment has achieved good results in clinical practice and scientific research. Multidisciplinary integrated therapy for tumors is not a simple combination of various treatment methods such as surgery, chemotherapy, radiotherapy, biological therapy and traditional Chinese medicine therapy, but a planned, step-by-step and sequential individualized treatment aggregate. Individualized tumor treatment plan should be reasonably designed according to patients’ general condition, pathological type and taking into account factors such as systemic condition and local condition, survival rate and quality of life, tumor load and body immune status, cost and benefit, Chinese medicine and western medicine. At the same time, tumor treatment should be combined and embraced in order to overcome drug resistance and improve efficacy, which includes chemotherapy, surgery, radiotherapy, targeted and immunotherapy. Through the orderly combined huddle, the efficacy can be realized to add up and the prognosis is better. Malignant tumors need precise diagnosis and treatment Tumor diagnosis and treatment cannot be blindly felt, and individualized and precise treatment plans need to be tailored for tumor treatment. The vision of precision oncology is to objectify subjective research, standardize objective research, individualize group research and make individual research precise. Finding potential targets and personalizing tailor-made drugs. Through precise diagnosis, precise treatment and precise prediction, we can “hit the nail on the head” and improve the therapeutic efficacy, and we should vigorously advocate the concept of precision medicine. Targeted immunotherapy may become the mainstream of tumor treatment in the future As the traditional tumor drug treatment generally refers to chemotherapy, with the characteristics of “no distinction between the enemy and me, you die and I live” and greater toxicity, nowadays, targeted and immunotherapy has become a more widely used means of treatment in the field of tumor treatment. Nowadays, molecular targeted therapy and immunotherapy have subverted the traditional treatment mode in the treatment of kidney cancer, non-small cell lung cancer, malignant melanoma and mesenchymal stromal tumor. Taking non-small cell lung cancer treatment as an example, in the past, the effective rate of traditional chemotherapy, i.e., the percentage of effective reduction of the scope of the lesion, always hovered around 20% to 30%, and the survival rate was 9 to 10 months. With molecular targeted therapy, the effective rate of treatment can be doubled to more than 50% to 60%, and the survival rate can be extended to 18 months if EFGR and ALK gene mutations are found in the patient’s genes through genetic examination prior to chemotherapy, and the physician administers targeted drugs that can inhibit such gene mutations. At the same time, this method in the treatment of intestinal cancer, breast cancer, lymphoma and other tumors, the effect is also significantly improved. Nowadays, many molecular targeted drugs are oral preparations, which are also more convenient and safer in terms of medication, creating conditions for many patients to be treated at home, and also providing the possibility of transforming malignant tumors into chronic diseases for treatment. Future: immunotherapy may cure malignant tumors In 2018, tumor immunotherapy won the Nobel Prize in Physiology and Medicine. Immunotherapy for tumors, as an innovative treatment modality, has become a major hotspot in the field of tumor treatment research. The design idea of “cancer immunotherapy” is to enhance the body’s own immune system to eliminate tumor cells in the body. In clinical treatment, we have found that immunotherapy has a synergistic effect with other treatments for tumor patients, and patients with good immune status have a longer remission period with immunotherapy. Therefore, on the basis of other treatments, combined immunotherapy will be a good treatment mode, and once successful, patients will be able to completely rely on their own immunity to cure the disease. Tumor immunotherapy is the key to future tumor treatment. With the in-depth research on the biological behavior of tumors, we have reason to believe that in the near future, tumor immunotherapy is expected to become the dominant treatment for most tumors.